☆ 4.6 Article

Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma

CANCERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Clinical determinants of long-term survival in metastatic uveal melanoma

Elias A. T. Koch et al.

Summary: The study identified that a good response to immune checkpoint blockade, radiation therapy, or liver-directed treatments were associated with prolonged overall survival. Conversely, a poor ECOG performance status and elevated serum LDH were linked to a poorer overall survival. Long-term survivors often had more organs affected by metastasis, while patients with liver metastases only were more common among short-term survivors.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Oncology

Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer

Alex K. K. Bryant et al.

Summary: This study demonstrates that pre-treatment NLR is a prognostic factor in stage III NSCLC patients treated with adjuvant immunotherapy, and it may also serve as a predictive biomarker of immunotherapy benefit.

LUNG CANCER (2022)

添加到收藏夹

Review Ophthalmology

Metastatic uveal melanoma: The final frontier

Elina S. Rantala et al.

Summary: Treatment of primary intraocular uveal melanoma has advanced significantly, but the risk of distant metastases remains high. There is no consensus on surveillance, staging, and treatment of disseminated disease, making it difficult to improve survival rates. Solving these issues is the key to curing metastatic uveal melanoma.

PROGRESS IN RETINAL AND EYE RESEARCH (2022)

添加到收藏夹

Article Oncology

MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

Mathilde Saint-Ghislain et al.

Summary: In patients with metastatic uveal melanomas, MBD4 mutations are associated with response to immune checkpoint inhibitors, progression-free survival, and overall survival benefits. MBD4 could serve as a predictive biomarker for the efficacy of ICI treatment.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Article Ophthalmology

High C-Reactive Protein Levels Are Related to Better Survival in Patients with Uveal Melanoma

Nikki Meijer et al.

Summary: This study aimed to investigate whether peripheral blood leukocyte numbers and serum markers of inflammation can predict metastasis in patients with primary uveal melanoma. The results showed that leukocyte numbers were associated with loss of BAP1 staining in patients who underwent enucleation, while high CRP levels were associated with longer metastasis-free survival in the entire cohort. However, neither the NLR nor the LMR were good predictors of metastasis in patients with uveal melanoma.

OPHTHALMOLOGY SCIENCE (2022)

添加到收藏夹

Article Oncology

Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

Jose Maria Piulats et al.

Summary: The combination of nivolumab and ipilimumab as first-line therapy for metastatic uveal melanoma patients showed a modest improvement in 12-month overall survival, with manageable toxicity profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Jiali Yu et al.

Summary: Liver metastases diminish the efficacy of immunotherapy by siphoning activated CD8(+) T cells from systemic circulation, creating systemic immune desert. Combining liver-directed radiotherapy with immunotherapy can promote systemic antitumor immunity.

NATURE MEDICINE (2021)

添加到收藏夹

Article Oncology

Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study

Meredith S. Pelster et al.

Summary: The combination regimen of nivolumab plus ipilimumab shows activity in metastatic uveal melanoma, yielding deep and sustained confirmed responses.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors

Jessica J. Waninger et al.

Summary: This study found that the AJCC eighth edition M category was poorly reflective of prognosis in patients receiving ICIs. Future staging systems could consider emphasizing the presence of liver metastases and elevated LDH levels. Additional studies are needed to confirm the importance of these and other prognostic biomarkers.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Medicine, General & Internal

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy A meta-analysis

Jun Xu et al.

Summary: This meta-analysis suggests that a higher pretreatment LDH level is significantly associated with worse overall survival and shorter progression-free survival in melanoma patients receiving anti-PD1/PD-L1 monotherapy.

MEDICINE (2021)

添加到收藏夹

Review Oncology

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma

Mariarosaria Marseglia et al.

Summary: Despite improvements in early identification and control of primary uveal melanoma, 50% of patients develop metastatic disease with little efficacy from targeted therapies. Immunotherapy, although effective in cutaneous melanoma, shows limited results in treating uveal melanoma due to its unique tumor microenvironment and immune responses.

CANCERS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Lars Ny et al.

Summary: The combination of HDAC inhibitor entinostat with anti-PD-1 antibody pembrolizumab shows durable responses in a subset of patients with metastatic uveal melanoma. Factors such as wildtype BAP1 gene, low tumor burden, and iris melanoma may be associated with better treatment response and longer survival.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Oncology

Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases

Brett M. Szeligo et al.

Summary: Uveal melanoma is a rare cancer originating from melanocytes in the eye, often leading to liver metastasis and poor long-term prognosis. Traditional chemotherapy and immunotherapy have limited efficacy in treating this disease, emphasizing the need for regional treatment approaches like isolated hepatic perfusion.

CANCERS (2021)

添加到收藏夹

Article Oncology

High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy

Edmund K. Bartlett et al.

CANCER (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review of liver directed therapy for uveal melanoma hepatic metastases

Alistair Rowcroft et al.

HPB (2020)

添加到收藏夹

Article Immunology

The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients

Ai-Ping Yang et al.

INTERNATIONAL IMMUNOPHARMACOLOGY (2020)

添加到收藏夹

Article Oncology

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study

Yana G. Najjar et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Oncology

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study

Jakob M. Riedl et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Comprehensive analysis of cutaneous and uveal melanoma liver metastases

Esmee P. Hoefsmit et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Review Oncology

Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma

Justine Cohen et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Ernesto Rossi et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)

添加到收藏夹

Review Oncology

Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives

Michela Croce et al.

CANCERS (2019)

添加到收藏夹

Article Oncology

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy

Mehmet Asim Bilen et al.

BMC CANCER (2019)

添加到收藏夹

Article Oncology

Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study

Markus Heppt et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

添加到收藏夹

Article Oncology

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

Kalijn Fredrike Bol et al.

CANCERS (2019)

添加到收藏夹

Review Oncology

Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis

Elina S. Rantala et al.

MELANOMA RESEARCH (2019)

添加到收藏夹

Article Oncology

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

Sanna Iivanainen et al.

ESMO OPEN (2019)

添加到收藏夹

Article Oncology

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Richard D. Carvajal et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors

Manuel Rodrigues et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients

Michael Constantin Kirchberger et al.

Oncotarget (2018)

添加到收藏夹

Article Oncology

Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

Aly-Khan A. Lalani et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Article Oncology

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

Mariaelena Capone et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

添加到收藏夹

Review Oncology

Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy

Yangbo Feng et al.

CANCER MEDICINE (2018)

添加到收藏夹

Review Ophthalmology

Metastatic disease from uveal melanoma: treatment options and future prospects

Richard D. Carvajal et al.

BRITISH JOURNAL OF OPHTHALMOLOGY (2017)

添加到收藏夹

Review Ophthalmology

Uveal melanoma: epidemiology, etiology, and treatment of primary disease

Benjamin A. Krantz et al.

CLINICAL OPHTHALMOLOGY (2017)

添加到收藏夹

Article Oncology

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E. Gershenwald et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2017)

添加到收藏夹

Article Oncology

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

Adi Nosrati et al.

BRITISH JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study

Tal Grenader et al.

BRITISH JOURNAL OF CANCER (2016)

添加到收藏夹

Article Oncology

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma

Matthew G. Field et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Oncology

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

P. F. Ferrucci et al.

BRITISH JOURNAL OF CANCER (2015)

添加到收藏夹

Article Oncology

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

Ester Simeone et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)

添加到收藏夹

Article Medicine, General & Internal

Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial

Richard D. Carvajal et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

Chih-Hao Chang et al.

CELL (2013)

添加到收藏夹

Article Immunology

Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells

Zaheed Husain et al.

JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Review Medicine, General & Internal

Circulating Serologic and Molecular Biomarkers in Malignant Melanoma

Shanique R. Palmer et al.

MAYO CLINIC PROCEEDINGS (2011)

添加到收藏夹

Article Medicine, General & Internal

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Article Oncology

Surgical management of liver metastases from uveal melanoma: 1.6 years' experience at the Institut Curie

P. Mariani et al.

EJSO (2009)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Review Multidisciplinary Sciences

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Matthew G. Vander Heiden et al.

SCIENCE (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.